eTRANSAFE

Enhancing Translational Safety Assessment through Integrative Knowledge Management

eTRANSAFE-logo-00
 
 
 
 
 
 
 

eTRANSAFE was a 40 Million EUR European project for new drug safety assessment and integrative data analysis research.
The five-year project aimed to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process and was funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) together with the pharmaceutical industry.

The eTRANSAFE consortium is a private and public partnership of 8 academic institutions, 6 SMEs and 12 pharmaceutical companies, and is coordinated by the Fundació Institut Mar d’Investigacions Mèdiques (IMIM) and led by the pharmaceutical company Novartis.
The eTRANSAFE project pursued the improvement of the safety assessment across the drug discovery and development process by applying bioinformatics approaches to shared preclinical and clinical data to systematically analyse the translatability of effects. Thus, enabling the optimisation of resources and the development of safer medicines.

Based on the experience gained in the previous eTOX project, the eTRANSAFE project was able to carry out key efforts in the field of data standardisation and quality control, promoting the development and implementation of relevant data sharing policies and procedures that will have a great global impact in the community. It catalysed the transformation of drug safety modelling from monolithic applications and isolated data repositories to an open innovation ecosystem based on open standards, modular components and data integration services.

For more information about eTRANSAFE project please visit: http://www.etransafe.eu/

eTRANSAFE was funded through the Innovative Medicines Initiative (IMI), and has received support from IMI2 Joint Undertaking under Grant Agreement No. 777365. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

EU-logo-00 efpia-logo-00 IMI-logo-00